|
gptkbp:instanceOf
|
gptkb:chemical_compound
benzodiazepine
antidepressant
|
|
gptkbp:approvedBy
|
gptkb:China
gptkb:Germany
gptkb:India
gptkb:Russia
gptkb:Switzerland
gptkb:Turkey
|
|
gptkbp:ATCCode
|
N06AA05
|
|
gptkbp:brand
|
gptkb:Insidon
gptkb:Opipramol-neuraxpharm
gptkb:Pramolan
|
|
gptkbp:CASNumber
|
315-72-0
|
|
gptkbp:chemicalClass
|
tricyclic compound
|
|
gptkbp:compatibleWith
|
gptkb:United_States
|
|
gptkbp:contraindication
|
narrow-angle glaucoma
acute urinary retention
prostatic hyperplasia
|
|
gptkbp:developedBy
|
gptkb:Germany
|
|
gptkbp:discoveredBy
|
gptkb:Ciba-Geigy
|
|
gptkbp:eliminationHalfLife
|
6-11 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:first_marketed
|
1961
|
|
gptkbp:hasMolecularFormula
|
C23H29N3O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Opipramol
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
antihistamine
anticholinergic
alpha-adrenergic antagonist
sigma receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
363.5 g/mol
|
|
gptkbp:PubChem_CID
|
4848
CHEMBL1201272
DB08815
|
|
gptkbp:relatedTo
|
gptkb:imipramine
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
constipation
dizziness
weight gain
drowsiness
dry mouth
|
|
gptkbp:UNII
|
A6T1F03GKE
|
|
gptkbp:usedFor
|
gptkb:depression
gptkb:somatoform_disorders
gptkb:generalized_anxiety_disorder
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|